Metabolic effect of sacubitril-valsartan combination: beware of hypoglycemia!

被引：0
作者：
Guetlin, M. [1 ]
Joubert, M. [1 ,2 ]
机构：
[1] CHU Caen, Serv Endocrinol Diabetol, Caen, France
[2] Univ Caen Normandie UNICAEN, Caen, France
来源：
CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION | 2024年 / 28卷 / 02期
关键词：
Sacubitril-valsartan; Heart failure with reduced ejection fraction; Diabetes; Hypoglycemia; NEPRILYSIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sacubitril-valsartan combination, a treatment for heart failure with reduced ejection fraction, also presents metabolic effects on glucose, particularly in patients with diabetes: several studies have shown a reduction in glycated hemoglobin (HbA1c), a reduction in insulin requirements, along with an increase of hypoglycemic risk. While the mechanisms of these metabolic effects are not fully understood, they may involve neprilysin inhibition and increased glucagon-like peptide-1 (GLP1) levels.
引用
收藏
页码：78 / 80
页数：3
相关论文
共 16 条
  • [1] Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers
    Antezana, MA
    Sullivan, SR
    Usui, ML
    Gibran, NS
    Spenny, ML
    Larsen, JA
    Ansel, JC
    Bunnett, NW
    Olerud, JE
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (06) : 1400 - 1404
  • [2] Severe Hypoglycemia in a Patient With Type 1 Diabetes Mellitus Recently Started on Sacubitril/Valsartan: A Case Report
    Barry, Arden R.
    [J]. CJC OPEN, 2020, 2 (03) : 176 - 178
  • [3] A Test in Context: Neprilysin Function, Inhibition, and Biomarker
    Bayes-Genis, Antoni
    Barallat, Jaume
    Richards, A. Mark
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (06) : 639 - 653
  • [4] Neprilysin deficiency reduces hepatic gluconeogenesis in high fat-fed mice
    Esser, Nathalie
    Mongovin, Stephen M.
    Mundinger, Thomas O.
    Barrow, Breanne M.
    Zraika, Sakeneh
    [J]. PEPTIDES, 2023, 168
  • [5] Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
    Esser, Nathalie
    Schmidt, Christine
    Barrow, Breanne M.
    Cronic, Laura
    Hackney, Daryl J.
    Mongovin, Stephen M.
    Hogan, Meghan F.
    Templin, Andrew T.
    Castillo, Joseph J.
    Hull, Rebecca L.
    Zraika, Sakeneh
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [6] Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with β-cell dysfunction
    Esser, Nathalie
    Mongovin, Stephen M.
    Parilla, Jacqueline
    Barrow, Breanne M.
    Mundinger, Thomas O.
    Fountaine, Brendy S.
    Larmore, Megan J.
    Castillo, Joseph J.
    Akter, Rehana
    Hull, Rebecca L.
    Zraika, Sakeneh
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2022, 322 (03): : E307 - E318
  • [7] Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
    Esser, Nathalie
    Zraika, Sakeneh
    [J]. DIABETOLOGIA, 2019, 62 (07) : 1113 - 1122
  • [8] Gamarra Elena, 2018, J Diabetes Sci Technol, V12, P1254, DOI 10.1177/1932296818785644
  • [9] Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure
    Kashiwagi, Yusuke
    Nagoshi, Tomohisa
    Kimura, Haruka
    Tanaka, Yoshiro
    Oi, Yuhei
    Inoue, Yasunori
    Ogawa, Kazuo
    Kawai, Makoto
    Yoshimura, Michihiro
    [J]. ESC HEART FAILURE, 2023, 10 (03): : 1860 - 1870
  • [10] Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect
    Kim, Heungjo
    Park, Gyunam
    Hahn, Jongsung
    Oh, Jaewon
    Chang, Min Jung
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
12